Bayesian fine-mapping of the top 25 AD GWAS loci will identify credible sets significantly enriched for variants disrupting microglia-specific regulatory elements, reflecting microglial dysfunction as a central AD pathogenic mechanism. Credible sets at loci with known effector genes (APOE, TREM2, PLCG2) will be smaller (<10 variants) due to stronger functional constraints, while novel loci will have larger sets requiring integration with epigenomic data to prioritize causal variants. The highest posterior probability variants will predominantly map to non-coding regulatory regions active in myeloid cells rather than neuronal or astrocytic enhancers.
No AI visual card yet
Curated Mechanism Pathway
Curated pathway diagram from expert analysis
flowchart TD
A["AD Fine-Mapping Microglia-Specific Enhancers"]
B["TREM2 Causal Variants Identified"]
C["Small Credible Sets Variant Refinement"]
D["Microglial Activation Phagocytosis Impact"]
E["TREM2 Variant as LOAD Risk Modifier"]
F["Enhancer-Based Therapeutic Targeting"]
A --> B
B --> C
C --> D
D --> E
E --> F
style A fill:#1a237e,stroke:#4fc3f7,color:#4fc3f7
style F fill:#1b5e20,stroke:#a5d6a7,color:#a5d6a7
Median TPM across 13 brain regions for TREM2 from GTEx v10.
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
7 citations7 with PMID5 mediumValidation: 42%5 supporting / 2 opposing
✓For(5)
5
No opposing evidence
(2)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Systematic CRISPRi fine-mapping of AD GWAS loci reveals heterogeneous causal cell types across loci; multiple …STRONG▼
Systematic CRISPRi fine-mapping of AD GWAS loci reveals heterogeneous causal cell types across loci; multiple risk genes implicate non-microglial mechanisms including neuronal and oligodendrocyte functions, challenging the prediction that most AD loci harbour microglia-specific enhancer variants
Genetic drivers of Alzheimer's disease progression are largely distinct from disease-risk loci and involve neu…MODERATE▼
Genetic drivers of Alzheimer's disease progression are largely distinct from disease-risk loci and involve neuronal pathways; this dichotomy suggests that relying on risk GWAS loci to infer microglial-enhancer causality may miss substantial non-microglial genetic architecture
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-21 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
[Error in hypothesis generation: complete() got an unexpected keyword argument 'tools']
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
The fundamental problem with this hypothesis is a category error: strong LD is a hindrance, not a help, for variant-level resolution. When variants are highly correlated, posterior probability diffuses across the LD block, making pinpointing the causal variant statistically harder, not easier. The hypothesis conflates "high statistical power to detect association" with "narrow credible sets."
The APOE/TOMM40 region is particularly problematic as an exemplar. De
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
[Error in expert assessment: complete() got an unexpected keyword argument 'tools']
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{"ranked_hypotheses":[],"synthesis_summary":"Synthesis could not be completed due to errors in receiving inputs from component agents. The Theorist, Skeptic, and Expert modules all returned errors stating 'complete() got an unexpected keyword argument tools', indicating a technical issue with agent invocation. Without validated hypotheses, critique, or feasibility assessments, no ranking or synthesis can be produced. Please verify the agent configuration and retry the generation pipeline.","knowledge_edges":[]}
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF Bayesian fine-mapping is performed on the top 25 AD GWAS loci using multi-ancestry summary statistics and high-resolution microglia ATAC-seq chromatin accessibility data, THEN the credible set variants at these loci will show significant enrichment (OR > 2.0, p < 0.001) for disruption of microglia-specific enhancers compared to null expectations from permuted genomic backgrounds within 6 months of analysis completion.
pendingconf: 0.78
Expected outcome: At least 18 of 25 loci (72%) will show enrichment scores for microglia-specific enhancer disruption > 2 standard deviations above genomic background null distribution; combined meta-analysis Fisher's exact test p-value < 1×10⁻⁶ for overrepresentation of myeloid-active regulatory variants.
Falsified by: Enrichment OR ≤ 1.0 or p > 0.05 for microglia-specific enhancer disruption among credible set variants; OR < 1.5 if nominally significant; or fewer than 12 of 25 loci showing any directional enrichment in microglia chromatin.
Method: Bayesian fine-mapping (SuSiE, CAVIAR, or FINEMAP) on N=1,126,523 AD cases/controls from PGC-ALZ, Regeneron, and UK Biobank cohorts, integrated with snATAC-seq from >50,000 microglia nuclei (AMP-AD, Banner, ROSMAP cohorts) and H3K27ac HiChIP contact maps from sorted human monocytes.
IF credible set sizes are compared between the three known effector gene loci (APOE, TREM2, PLCG2) and the remaining 22 novel AD loci after Bayesian fine-mapping, THEN the median 95% credible set at effector gene loci will contain <10 variants while novel loci will have median sets >25 variants (Mann-Whitney U p < 0.001) within 6 months of analysis completion.
pendingconf: 0.72
Expected outcome: Mean 95% credible set size at APOE/TREM2/PLCG2 = 6.3 variants (range 3-9); mean 95% credible set size at novel loci = 31.7 variants (range 18-89); ratio of novel/effector set sizes > 3.5; at least 2 of 3 effector loci reducing to ≤5 variants when integrating microglia Hi-C loops.
Falsified by: No significant size difference (p > 0.05) between effector and novel loci credible sets; median effector gene credible set size ≥15 variants; or >50% of known effector loci showing credible sets larger than the median novel locus set.
Method: Comparative analysis of 95% credible sets from SuSiE fine-mapping pipeline applied uniformly across 25 AD loci, stratified by prior evidence for effector gene candidacy (genomic annotations, eQTL colocalization, rare variant burden); bootstrapped 95% CI for set size distributions calculated from 1000 resamples.